Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists

Authors

  • Jun Kawakami Department of Urology, Queen’s University, Kingston, ON
  • Alvaro Morales Department of Urology, Queen’s University, Kingston, ON

DOI:

https://doi.org/10.5489/cuaj.540

Keywords:

Prostatic neoplasms, Testosterone, Androgen antagonists

Abstract

Purpose:  We examined the serum levels of testosterone (T) (total and bioavailable) dehydroepiandrosterone (DHEA), follicle stimulating (FSH), luteinizing (LH), and prostate specific antigen (PSA) in men receiving treatment with  luteinizing hormone releasing-hormone (LHRH) agonists for metastatic prostate cancer, to determine the efficacy of these agents in lowering T levels and whether a possible  relationship exists between PSA values, as a surrogate measure of tumor activity, and hormone levels.

 

Materials and Methods:  This was a single center prospective study of patients on LHRH agonists.  Of all 100 eligible patients, 31 did not qualify: 10 were receiving their first injection, 13 were on intermittent hormonal therapy, 7 refused to enter the trial, and 1 patient’s blood sample was lost.  Therefore, 69 patients were included in the final analysis.  Each patient had their blood sample drawn immediately before the administration of a LHRH agonist. The new proposed criteria of <20ng/dL (0.69 nmol/L) of total testosterone was used to define optimal levels of the hormone in this population.

 

Results: Of the 69 patients, 41 were on goserelin injections, 21 on leuprolide, and 7 on buserelin.  There was no statistical difference in hormone levels between any of the medications.  Overall, 21% of patients failed to reach optimal levels of total testosterone. PSA levels were higher in this group.  There was a statistically significant correlation between PSA and testosterone levels as well as between PSA and  FSH.  Serum levels of PSA however, did not correlate with those of bio-available testosterone.

 

Conclusions: Failure to reach optimal levels of testosterone occurs in patients on LHRH agonist therapy.  Higher PSA values are more commonly found in patients with sub-optimal levels of testosterone receiving LHRH analogs but the clinical importance of this finding has not been established.  There is no significant difference with respect to hormonal levels reached among patients on a variety of LHRH agonists.  Total testosterone determinations should be considered in patients on LHRH agonist therapy, particularly when the PSA values begin to rise since it may lead to further beneficial hormonal manipulation.

Downloads

Download data is not yet available.

Downloads

Published

2013-04-16

How to Cite

Kawakami, J., & Morales, A. (2013). Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists. Canadian Urological Association Journal, 7(3-4), e226–30. https://doi.org/10.5489/cuaj.540

Issue

Vol. 7 No. 3-4 (2013): CUAJ April

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.